Nurix Therapeutics Announces Key Additions to its Board of Directors

Decibel Therapeutics to Provide Corporate Update at Jefferies Gene Therapy Summit

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

GBT Announces New Employment Inducement Grants

PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at OIS@AAO

Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD

Goldfinch Bio Announces Licensing Agreement with Takeda for Cb1 Monoclonal Antibody for the Treatment of Rare and Metabolic Kidney Diseases

GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention

Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GBT to Host Analyst & Investor Day on October 8 in New York

Relay Therapeutics Names Jami Reubin to its Board of Directors

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting

Editas Medicine to Participate in Upcoming Investor Conferences

Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors

Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference

MyoKardia to Present at 2019 Cantor Global Healthcare Conference

GBT Announces Participation at the 2019 Cantor Global Healthcare Conference

Rhythm Pharmaceuticals Provides Update on Research and Development Programs

Voyager Therapeutics To Present At Upcoming Investor Conferences In October 2019

Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company

Thrive Earlier Detection Announces Appointment of Seema Singh Bhan as Senior Vice President, Public Policy and External Affairs

FierceBiotech names Celsius Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

FierceBiotech names Maze Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

insitro Announces Key Leadership Appointments

Researchers Shed Light on Bladder Cancer Population Not Receiving Curative Intent Therapy

Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase

Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Zafgen to Explore Strategic Alternatives

Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine

Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team

GBT Announces New Employment Inducement Grants

Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders

Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder